Rhythm Pharmaceuticals Operating Income Over Time
| RYTM Stock | USD 99.73 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rhythm Pharmaceuticals Performance and Rhythm Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Rhythm diversify its offerings? Factors like these will boost the valuation of Rhythm Pharmaceuticals. Anticipated expansion of Rhythm directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Rhythm Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Rhythm Pharmaceuticals and related stocks such as Revolution Medicines, Akero Therapeutics, and Avidity Biosciences Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (40.3 M) | (54.1 M) | (110.7 M) | (188 M) | (258.3 M) | (487.2 M) | (689.5 M) | (620.6 M) | (589.5 M) |
| RNA | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (17.3 M) | (44.3 M) | (118.1 M) | (178.9 M) | (235.6 M) | (378.9 M) | (341 M) | (324 M) |
| PTGX | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (14.8 M) | (32.7 M) | (37.9 M) | (42.3 M) | (80.5 M) | (64.5 M) | (125.8 M) | (131.4 M) | (93.7 M) | 252.8 M | 290.8 M | 305.3 M |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.8 M) | (35.7 M) | (53 M) | (86.1 M) | (104.4 M) | (114.8 M) | (101.4 M) | (91.2 M) | (95.8 M) |
| QURE | (22.2 M) | (22.2 M) | (18.8 M) | (31.1 M) | (41.1 M) | (74.8 M) | (71.9 M) | (72 M) | (88.2 M) | (121.1 M) | (125.4 M) | 310.6 M | (143.2 M) | (282.9 M) | (184.3 M) | (165.9 M) | (157.6 M) |
| RCKT | (5.8 M) | (5.8 M) | (5.8 M) | (6.7 M) | (7.7 M) | (20.4 M) | (41.9 M) | (26.7 M) | (71.2 M) | (76.2 M) | (136 M) | (167.2 M) | (224.3 M) | (259.7 M) | (273.2 M) | (245.9 M) | (233.6 M) |
| SLDB | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (25.6 M) | (54.9 M) | (75.7 M) | (119.3 M) | (86.5 M) | (72.3 M) | (106.5 M) | (104.3 M) | (129.7 M) | (116.8 M) | (122.6 M) |
| MGTX | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (31.7 M) | (78.1 M) | (58.3 M) | (62.6 M) | (72.8 M) | (116.4 M) | (137.1 M) | (164.2 M) | (147.8 M) | (140.4 M) |
| NUVL | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (16.9 M) | (45.8 M) | (86.1 M) | (149.5 M) | (280.4 M) | (252.3 M) | (239.7 M) |
| VTYX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (7 M) | (67.1 M) | (113.1 M) | (208 M) | (148.4 M) | (133.6 M) | (140.3 M) |
| ACLX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (18 M) | (32.1 M) | (65 M) | (191.3 M) | (89.9 M) | (137.6 M) | (123.8 M) | (130 M) |
| CGEM | (699 K) | (699 K) | (699 K) | (699 K) | (128.8 K) | (95.4 K) | (197.4 K) | (14.6 M) | (14.6 M) | (22.3 M) | (60.3 M) | (68 M) | 144.6 M | (191.1 M) | (196.9 M) | (177.2 M) | (168.4 M) |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (65.4 M) | (108.2 M) | (170 M) | (157.4 M) | (156.6 M) | 9.8 M | (25.2 M) | (45.6 M) | (52.5 M) | (55.1 M) |
| PLRX | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (30.9 M) | (1.2 M) | (41.6 M) | (20 M) | (127.2 M) | (184.1 M) | (228.4 M) | (205.5 M) | (195.3 M) |
| SNDX | (9.6 M) | (9.6 M) | (8.7 M) | (8.6 M) | (21.3 M) | (20.5 M) | (43.8 M) | (62 M) | (75.9 M) | (57.5 M) | (71.4 M) | 26.2 M | (151.8 M) | (230 M) | (339.7 M) | (305.7 M) | (290.4 M) |
| VRDN | (4 M) | (4 M) | (4 M) | (196.2 K) | (6.9 M) | (11.2 M) | (12.5 M) | (26.5 M) | (33.1 M) | (42 M) | (110.4 M) | (79.7 M) | (134.3 M) | (254.4 M) | (299 M) | (269.1 M) | (255.7 M) |
| RLAY | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (84 M) | (55.8 M) | (364.7 M) | (299.3 M) | (373 M) | (372.5 M) | (335.2 M) | (352 M) |
| BDTX | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (8.9 M) | (8.9 M) | (69.6 M) | (126.9 M) | (92.8 M) | (86.5 M) | (78.8 M) | (70.9 M) | (74.4 M) |
| ARVN | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (24.8 M) | (43.8 M) | (51.5 M) | (124.9 M) | (195.3 M) | (263.2 M) | (401.5 M) | (250.2 M) | (225.2 M) | (236.4 M) |
Rhythm Pharmaceuticals and related stocks such as Revolution Medicines, Akero Therapeutics, and Avidity Biosciences Operating Income description
Operating Income is the amount of profit realized from Rhythm Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rhythm Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Rhythm Pharmaceuticals | RYTM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 222 Berkeley Street, |
| Exchange | NASDAQ Exchange |
USD 99.73
Check out Rhythm Pharmaceuticals Performance and Rhythm Pharmaceuticals Correlation. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Rhythm Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.